Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide and anlotinib plus AG versus AG in advanced or recurrent pancreatic cancer
ChiCTR2500095869Phase 2Not yet recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tucidinostat, anlotinib, paclitaxel and gemcitabine in pancreatic cancer (PC) (3 arms), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoint: Objective response rate. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
tucidinostatanlotinibpaclitaxelgemcitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2500095869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095869.